Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924 [PMID: 38077638 DOI: 10.4251/wjgo.v15.i11.1913]
Corresponding Author of This Article
Baruch Brenner, MD, Professor, Institute of Oncology, Davidoff Cancer Center, Beilinson Campus, 39 Jabotinski Street, Petah-Tikva 4941492, Israel. brennerb@clalit.org.il
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924 [PMID: 38077638 DOI: 10.4251/wjgo.v15.i11.1913]
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1913-1924 Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913
Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer
Baruch Brenner, Aaron Sulkes, Yosef Landman, Michal Sternschuss, Gil Mullin
Gil Mullin, Aaron Sulkes, Baruch Brenner, Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel
Gil Mullin, Michal Sternschuss, Yosef Landman, Aaron Sulkes, Baruch Brenner, Institute of Oncology, Davidoff Cancer Center, Beilinson Campus, Petah-Tikva 4941492, Israel
Author contributions: Brenner B, Sternschuss M, and Mullin G contributed to study design; Mullin G contributed to acquisition of data; Mullin G, Sternschuss M, Brenner B, Sulkes A, and Landman Y contributed to data analysis and interpretation; Mullin G, Sternschuss M, Brenner B, and Sulkes A contributed to manuscript writing; Mullin G, Sternschuss M, Brenner B, Sulkes A, and Landman Y contributed to final manuscript approval.
Institutional review board statement: The study was reviewed and approved by the Rabin Medical Center Institutional Review Board (Approval No. 0639-19-RMC).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at brennerb@clalit.org.il. Consent was not obtained but the presented data are anonymized and risk of identification is low.
Corresponding author: Baruch Brenner, MD, Professor, Institute of Oncology, Davidoff Cancer Center, Beilinson Campus, 39 Jabotinski Street, Petah-Tikva 4941492, Israel. brennerb@clalit.org.il
Received: May 23, 2023 Peer-review started: May 23, 2023 First decision: July 31, 2023 Revised: August 31, 2023 Accepted: October 11, 2023 Article in press: October 11, 2023 Published online: November 15, 2023 Processing time: 176 Days and 3.9 Hours
Core Tip
Core Tip: Survival with metastatic colorectal cancer has improved significantly. However, when the disease becomes refractory, patients are left with limited options. Mitomycin C (MMC) and capecitabine combination is a potential treatment option for metastatic colorectal cancer (mCRC) patients beyond standard lines of treatment. Only a few small studies have tested it in the advanced-line setting, with contradictory results. We present our experience using the MMC/capecitabine combination. Our findings suggest that MMC/capecitabine is a safe, generally well-tolerated regimen. Ours is the largest series on the use of MMC/capecitabine in refractory mCRC. We were able to identify well-defined subgroups which derived clinical benefit from this combination.
